Related pathways do not make identical medicines
Sermorelin is an analogue of growth-hormone-releasing hormone, a signaling hormone. Growth hormone itself is a different substance. Tesamorelin is another growth-hormone-releasing hormone analogue with its own formulation and clinical history. These distinctions matter whenever a website uses a broad label such as “growth hormone therapy” or “peptide support.”
Before reading a price comparison or benefit claim, ask which molecule and finished product it refers to. A shared biological pathway does not establish interchangeable dosing, clinical effects, approved uses or safety. This guide does not provide a conversion between them.
Geref is a historical finished product
FDA's 2013 notice describes the former Geref sermorelin acetate products, including a treatment formulation for growth failure in children with idiopathic growth-hormone deficiency and a diagnostic formulation for evaluating pituitary growth-hormone secretion. Their approvals and indications were specific to those products. The notice also records that their approvals were withdrawn in 2009 after discontinuation requests.
FDA subsequently determined that the named products had not been withdrawn from sale because of safety or effectiveness. That historical finding is not a new approval for today's compounded sermorelin injections, lozenges or adult anti-aging programs.
Tesamorelin approval has a defined population
The Egrifta label identifies tesamorelin for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not a general weight-loss indication. A benefit demonstrated for that indication does not become proof of the same benefit in a different population or with a different peptide.
If a provider discusses tesamorelin and sermorelin together, ask which evidence supports the medication actually being proposed. Also distinguish an approved branded tesamorelin product from a compounded formulation. Sharing an active ingredient name does not give a compounded product the branded product's FDA approval.
Growth-hormone deficiency is a clinical diagnosis
The Endocrine Society's guideline concerns evaluating and treating adult growth-hormone deficiency. It should not be interpreted as an endorsement of every program promising to optimize age-related hormone changes. The guideline emphasizes individualized clinical judgment and ordinarily uses confirmatory stimulation testing, with particular exceptions.
A person's age, a symptom list or an online questionnaire cannot by itself resolve all those diagnostic questions. Ask the clinician whether a deficiency is being evaluated, what alternatives should be considered and why the proposed treatment matches the actual clinical situation.
Use the distinctions in a real comparison
Write down the exact molecule, route, finished product, proposed purpose and supporting evidence before comparing costs. A package that substitutes another peptide or combines ingredients is a different offer. Keep those differences visible instead of reducing all options to a single “growth hormone” monthly price.
FDA explains that compounded drugs are not approved and do not undergo its premarket review for safety, effectiveness and quality. Pharmacy licensing and clinician involvement have roles, but neither erases that distinction. A careful comparison connects a named prescription with a specific medical rationale rather than borrowing another product's approval or trial results.
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.